The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen

Author： Vincenzi Bruno   Santini Daniele   Frezza Anna Maria   Berti Pierpaolo   Vespasiani Umberto   Picardi Antonio   Tonini Giuseppe  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.3, 2011-05, pp. : 345-349

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

XELOX dominant over FOLFOX4 for colorectal cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 585, 2009-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Removing oxaliplatin from FOLFOX feasible in colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1528, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

FOLFOX4: clear benefit in colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1347, 2002-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Adding cytokine-induced killer (CIK) cell therapy to the FOLFOX4 regimen is beneficial for treating advanced gastric cancer

By  

Inpharma, Vol. 1, Iss. 1548, 2006-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis

By Martin Robert C. G.   Scoggins Charles R.   Schreeder Marshall   Rilling William S.   Laing Christopher J.   Tatum Clifton M.   Kelly Lawrence R.   Garcia-Monaco Ricardo D.   Sharma Vivek R.   Crocenzi Todd S.   Strasberg Steven M.  

Cancer, Vol. 121, Iss. 20, 2015-10 ,pp. : 3649-3658

Blackwell Publishing

Access to resources Recommend Favorite